By targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic peptide receptors, tirzepatide reduces hunger signals, slows gastric emptying, and improves insulin sensitivitymechanisms supported by Phase 3 SURMOUNT clinical trials showing 22.5% weight reduction over 68 weeks
Interestingly, in GLP-1R-deficient mice, liraglutide loses its beneficial effects (Steven et al., 2017)
Here we show that an uncharacterized Buchnera protein, designated SyeA, was present in the Buchnera ancestor, is secreted into the host cytoplasm, is homologous to secreted effectors of bacterial pathogens and is essential for Buchnera transmission
10.1016/j.fitote.2011.01.020 125 NoureiniS
Tirzepatide: As a newer option, Tirzepatide targets both GLP-1 and GIP receptors, making it a unique choice for those exploring different weight management solutions